

8. Előadás

Peptidek


Jelentkeztek: 39 fő

Jelen voltak: 27 fő

Név	Kód	%
Bödecs András	FM1BO9	71,8
Pozsgai Balázs	FSVV6K	94.9
Sági István	F937VV	76.9
Szigeti Szilvia	FD42VK	83.3


> 50 % : 6 fő

Peptid szintézis: a koncepció



Keverék, alacsony konverzió

2. Megoldás



Egyféle termék, magas konverzió


3. Követelmények

3.1. Védőcsoportok, egyszerű beépítés, egyszerű eltávolítás


3.2. Hatékony kapcsolási reakció

Négy lépés


4.1. Védett (N-, C- és oldallánc) aminosavszármazékok




4.2. A C-terminálison „aktivált” aminosavszármazék szintézise



4.3. Kapcsolás



4.4. Védőcsoportok eltávolítása



1. Védőcsoportok

„All modern work in Peptide synthesis employs the following approach: the amino group of one amino acid is first stabilized by the introduction of a protecting group R, the carboxy group is modified so that it is capable of coupling, and finally the R group is removed to produce the finished peptide. The difficulty lies in finding a suitable group R, which can be removed so gently that the peptide is not significantly attacked.”

Bergman, M., Zervas, L.: Berichte Chem. 65, 1192 (1932)

Csoportosítás


1. N^{α} - védőcsoport
2. C^{α} - védőcsoport
3. Oldallánc védőcsoport

1.1. N^α-Amino csoport védelme

1.1.1. Benziloxi-karbonil (Z)

Bergman, M., Zervas, L. : Berichte Chem. 65,1192 (1932)


Beépítés



Benziloxikarbonil klorid


Benziloxikarbonil aminosav

Eltávolítás



Hasítási mechanizmus


Benziloxi-karbonil




1.1.2. *t*-Butiloxi-karbonil (Boc)

Carpino, L.A. et al. JACS (1957)

Beépítés




Eltávolítás




1.1.3. 9-Fluorenilmetoxi-karbonil

Carpino, L.A. et al. JACS 92, 5748 (1970)

Beépítés




Eltávolítás




1.2. Karboxi védelem

Észter kötés kialakítása



Eltávolítás



1.3. Oldallánc védelem

1.3.1. Glu, Asp

1.3.2. Lys

1.3.3. Ser, Thr, Tyr


1.3.4. Arg

1.3.5. His


1.3.6. Trp

1.3.7. Cys


-OH védőcsoport



Benzil (éter)
(Bzl)




terc-Butil (éter)
(t-Bu)




Tritil*
(Trt)

Eltávolítás





* csak Ser/Thr


-SH védőcsoport




Imidazol védőcsoport



Tritel
(Trt)




4-Metiltritel
(Mtt)




4-Metoxitritel
(Mmt)

Guanidino védőcsoport



4-Toluolszulfonil*
(Tos)

* HF vagy Na/NH₃




4-Metoxi-2,3,6-trimetilbenzolszulfonil
(Mtr)

Az optimális védőcsoport - összegzés

1. Könnyű és hatékony beépülés.
2. A peptidkötés érintetlensége a beépítés/eltávolítás alatt.
3. Több mint egyféle eltávolítási lehetőség.
4. Nincs racemizáció.
5. A melléktermékek egyszerű és könnyű eltávolítása.
6. A reakciók szobahőmérsékleten menjenek végbe.


2. lépés: Az aminosav „aktiválása”

2.1. A karbonsav származékok aktivitása




2.2. A karbonsav származékok aktiválása


2.2.1. Acil azid (T. Curtius, Berichte Chem. 35, 3226, 1902)




2.2.2. Actív észter (M. Bodanszky, Nature, 175, 685, 1955; J. Kovacs, JACS, 89, 183, 1967; L. Kisfaludy, Liebigs Ann. 1421, 1973)




2.2.3. Anhidrid (vegyes) (E. Fischer, Berichte Chem. 36, 2094,1903;
T. Wieland, Liebigs Ann. 569, 122, 1950)



2.2.4. Anhidrid (szimmetrikus) (F. Weygand et al., Z. Naturf. 22, 1084, 1967)




2.2.5. Karbodiimid (J.C. Sheenan, G.P. Hess, JACS, 77, 1067, 1955)




3. lépés: A peptidkötés kialakítása

3.1. Acil azid (nincs racemizáció)




3.2. Aktív észter (S_N)




3.3. Anhidrid


szimmetrikus



aszimmetrikus




3.4. Karbodiimid




Racemizáció

Az enantiomer átalakulása enantiomer keverékké




A racemizáció mechanizmusa

a: direkt enolizáció



b: oxazolon képződés*



* :B nélkül :N iniciálja a reakciót


Poláros fény

Looking at two polarized lenses at the same time, by rotating one of the lenses, we can either let light through, or we can stop the light all together.



How does it work?

Visible Light is a form of electromagnetic Radiation. So we know that visible light acts like a wave. The wave motion forces light to vibrate sideways. So, when light moves forward, it is also vibrating sideways.




In the light that we see, some light vibrates up and down.

Some light that we see vibrates right and left.

If we were to look at enough light photons, we find that each photon vibrates in a different direction. So in a beam of light different light photons vibrate in all directions.




Experiment 1



You can still see light, since both lenses allow the light that vibrates up and down to pass through.

Experiment 2




No Light Comes out of the 2nd Polarized Lens!




Polarimeter

Used to measure the optical rotation of molecules in solution


The Polarimeter Tube contains an optically active substance (such as an Amino Acid) in a solution which causes the plane of polarized light to rotate.



A racemizáció és a kormeghatározás




Stratégiák: Szegmens kondenzáció




↓ Részleges hasítás /
aktiválás

↓ Részleges hasítás




Stratégiák: Lépésenkénti hosszabbítás

A) C-terminálison



B) N-terminálison





Bruce R. Merrifield

There is a need for rapid, quantitative, automatic method for the synthesis of long peptides.


A possible approach may be the use of chromatographic columns, where the peptide is attached to the polymer packing and added to an activated amino acid followed by removal of protecting group, with repetition of the process until the desire peptide is built up.

Finally the peptide must be removed from the supporting medium.

R.B.Merrifield Laboratory note book (1959)

JACS 85, 2149 (1963)

A szilárd fázisú peptidszintézis elve



A szilárd fázisú peptid szintézis főbb szempontjai


A. A szilárd felszín

1. Tartalmazzon reaktív csoportokat funkcionálizálásra
2. Peptid-polimer kötés hasítható legyen
3. Stabil legyen a szintézis körülményei között
4. A peptidlánc hozzáférhető legyen az oldószer és a reagensek számára

B. Védőcsoport kombinációk

1. Peptid-polimer kötés stabil legyen a szintézis alatt
2. „Átmeneti” védőcsoport az α -amino csoporton
3. „Állandó” védőcsoport az oldalláncokon
4. Hatékony hasítás.


Védőcsoport típusok a szilárd fázisú szintézisben




- a. N^α - védőcsoport („átmeneti“)
- b. Oldallánc védőcsoportok („állandó“)
- c. Gyanta-peptid kötés




Boc/benzil stratégia - Merrifield módszer




Fmoc/t-butil stratégia - Sheppard módszer




Lineáris szintézis




Konvergens szintézis




Szilárd fázisú peptid szintézis: Összegzés



Mit találhatunk a szintézis „nyers” termékében ?




Szintézis „formák”




Kombinatorikus szintézis: keverés-osztás elv



Furka et al. Int. J. Pept. Prot. Res. (1991)




A TQTX²T alpeptid tárok szintézise



T-**R**








Folt (spot) peptidszintézis





Alkalmazások




D

Metal-Binding




E


Antimicrobial Peptide Assay




Néhány „fontos” peptid




Glutation



Oxitocin




Vazopresszin



Inzulin

Hasnyálmirigy hormonja



Izolálás: 1922 Banting Primer

Szerkezet: 1953 Sanger

Szintézis: 1969 Zahn, Wang, Katsoyannis

Térszerkezet: 1965 Hodgkin

ATCH

39 aminosav

Sertés: szintézis Schwitzer, 1963

Humán: szintézis Bajusz, Kisfaludy, Medzihradszky 1971